uniQure (NASDAQ:QURE) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of uniQure (NASDAQ:QURE) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

QURE has been the subject of a number of other reports. Weiss Ratings upgraded uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Royal Bank Of Canada decreased their price target on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating for the company in a research note on Friday, October 2nd. Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a report on Wednesday, July 29th. UBS Group assumed coverage on uniQure in a research note on Thursday, October 15th. They issued a “buy” rating and a $48.00 price objective on the stock. Finally, The Goldman Sachs Group reduced their price objective on uniQure from $46.00 to $31.00 and set a “neutral” rating on the stock in a report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $56.83.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $21.70 on Friday. uniQure has a 1 year low of $8.73 and a 1 year high of $51.72. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.52 and a quick ratio of 10.01. The stock has a market cap of $1.52 billion, a PE ratio of -6.18 and a beta of 1.14. The firm has a fifty day moving average price of $31.86 and a 200-day moving average price of $29.68.

uniQure (NASDAQ:QURE) last released its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $6.17 million. uniQure had a negative net margin of 1,154.84% and a negative return on equity of 96.34%. Equities analysts anticipate that uniQure will post -3.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

Several institutional investors have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. lifted its stake in shares of uniQure by 107.3% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company’s stock worth $6,546,000 after purchasing an additional 73,566 shares during the last quarter. Royal Bank of Canada grew its stake in uniQure by 26.0% in the first quarter. Royal Bank of Canada now owns 107,888 shares of the biotechnology company’s stock valued at $1,763,000 after purchasing an additional 22,248 shares during the last quarter. Kalehua Capital Management LLC purchased a new position in uniQure in the first quarter valued at about $4,760,000. Orbimed Advisors LLC grew its stake in uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in uniQure by 249.9% in the second quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock worth $23,653,000 after purchasing an additional 366,781 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.